Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies
Open Access
- 1 January 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Clinical Interventions in Aging
- Vol. 8, 75-84
- https://doi.org/10.2147/cia.s37818
Abstract
Peer reviewed article authored by (Amin A). Read article or submit your manuscript for publishing.Keywords
This publication has 49 references indexed in Scilit:
- Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or DabigatranStroke, 2012
- Executive SummarySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial FibrillationThe American Journal of Medicine, 2011
- Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarinGenetics in Medicine, 2008
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care systemCurrent Medical Research and Opinion, 2005
- Status of Antithrombotic Therapy for Patients With Atrial Fibrillation in University HospitalsArchives of Internal Medicine, 1996
- Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.1995